CEMIP and breast carcinoma: reported that silencing CEMIP, which was enriched in brain‐tropic EVs in comparison to lung‐tropic or bone‐tropic EVs, dramatically hindered the brain metastasis of breast cancer cells.[35] Consistently, our data demonstrated that silencing VAPA in HCC cells consequently resulted in VAPA reduction in HCC‐derived LOs, or treatment with anti‐VAPA antibody significantly abolished HCC‐derived LOs‐induced formation of the bone‐metastatic niche and HCC bone metastasis.